AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Investigation of Specific Protein/Markers in Patients With Osteoarthritis of the Knee Having a Total Knee Replacement
Completed
- Conditions
- Osteoarthritis of the Knee
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2012-06-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 125
- Registration Number
- NCT01611441
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
🇨🇦Research Center, Newmarket, Canada
A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta
Completed
- Conditions
- Acute Coronary Syndromes
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3402
- Registration Number
- NCT01611272
- Locations
- 🇰🇷
Research Site, Ulsan, Korea, Republic of
The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2165
- Registration Number
- NCT01608724
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese Subjects
Phase 1
Completed
- Conditions
- Healthy Japanese Volunteers
- Interventions
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT01608542
Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Metastatic Cancer,Non-Small Cell Lung CancerNeoplasms,Advanced Solid Malignancies
- Interventions
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2016-10-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 33
- Registration Number
- NCT01605916
- Locations
- 🇯🇵
Research Site, Nagoya-shi, Japan
Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1282
- Registration Number
- NCT01606007
- Locations
- 🇺🇸
Willamette Valley Clinical Studies, Eugene, Oregon, United States
🇺🇸Pmg Research Of Knoxville, Knoxville, Tennessee, United States
🇺🇸Excel Clinical Research, Llc, Houston, Texas, United States
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT01604733
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Phase 2
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: AZD3241 300 mg BIDDrug: AZD3241 600 mg BIDDrug: Placebo
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 51
- Registration Number
- NCT01603069
- Locations
- 🇺🇸
Research Site, Marlton, New Jersey, United States
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 343
- Registration Number
- NCT01603082
- Locations
- 🇺🇸
Research Site, Richmond, Virginia, United States
A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
Phase 3
Active, not recruiting
- Conditions
- Hormone Receptor Positive Breast Cancer
- Interventions
- First Posted Date
- 2012-05-21
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 462
- Registration Number
- NCT01602380
- Locations
- 🇬🇧
Research Site, Stoke-on-Trent, United Kingdom